On September 25, 2024, Windtree Therapeutics, Inc. (the “Company”) issued a press release announcing positive topline results from the Company’s Phase 2b SEISMiC Extension Study of istaroxime in treating early cardiogenic shock due to heart failure. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Eightco Announces $100 million Revenue Forecast – Releases 2025 Strategic Plan

Vertex Energy and Its Lenders Initiate Formal Pathway Aimed at Achieving Sustainable Capital Structure

What leaked

Don’t blink

Le Mans Ultimate Releases Innovative Co-op Game Mode, Save & Load System and 2024 Pack 2 DLC

AMMO, Inc. Appoints New Chief Financial Officer and Provides Corporate Update

ParaZero Receives $187,000 Purchase Order for Advanced Drone Safety Systems Moving Towards Serial Production

Lol

Hilarious watching l2 all day here

Mm keeping the spread to a penny

Halt

911 what’s your emergency? Ahhhh…..

LOL

These bums

XChange TEC.INC Announces Entry into $25.0 Million Committed Equity Facility with VG Master Fund SPC

Manipulated computer generated trading what else is new

Have at it if you want

This is going to end badly

Capricor Therapeutics Announces Intent to File Biologics License Application for Full Approval of Deramiocel for the Treatment of Duchenne Muscular Dystrophy Cardiomyopathy

Banzai Announces $24.8 Million Debt Payoff and Restructuring Agreements with Participation from Company Insiders

Don’t blink

Yawn….

Scary to think algo’s moves this above $3

Don’t mess with machines

Silexion Therapeutics Announces Significant New Data from Phase 2 Trial of LODER™ in Non-Resectable Pancreatic Cancer

Yikes

PayMate Announces Intent to Acquire DigiAsia

Don’t blink

Don’t blink

That PR…. Hard not to laugh

Delta Corp Holdings Limited, a Fast Growing Asset-Light Logistics Company Enters into a Definitive Merger and Share Exchange Agreement with Kaival Brands Innovations Group, Inc.

Who’s poking it?

Yawn…

Ventyx Biosciences Announces $27 Million Strategic Investment from Sanofi

Bimbos

Black Diamond Therapeutics Announces Initial Phase 2 Data Demonstrating Robust Anti-tumor Activity of BDTX-1535 in Patients with Recurrent EGFRm NSCLC who Present with a Broad Spectrum of Classical, Non-classical, and C797S Resistance Mutations

Whoops

Now now

Tread lightly

“Overcooked” burger coming right up

Solid day. They filled 50-100k plus of shares at $11 bucks last night AH

YIKES!!!

Whoops

Boo hoo